SEC 13F Intelligence

Managers / Q3 2025 · view latest →

Artia Global Partners LP

CIK 0001937964 · 1 SE 3RD AVENUE, STE 2120, MIAMI, FL, 33131 · 3057101384

Reported Value
$631M
Q3 2025
Positions
51
Filings on Record
15
2019–present window
Filed
Nov 14, 2025
amendment (RESTATEMENT)

Summary

Artia Global Partners LP reported $631M in U.S.-listed holdings across 51 positions for Q3 2025.

Its largest position, INSM, represents 16.7% of the portfolio.

Compared with Q2 2025, the fund opened 16 new positions and exited 3.

Portfolio Metrics

Turnover
+13.5%
vs prior filed quarter
Top-10 Concentration
+63.9%
share of reported value
Largest Position
+16.7%
Insmed
New / Exited
16 / 3
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’22: $262MQ4 ’22Q1 ’23: $271MQ2 ’23: $290MQ2 ’23Q3 ’23: $241MQ4 ’23: $344MQ4 ’23Q1 ’24: $498MQ2 ’24: $517MQ2 ’24Q3 ’24: $367MQ4 ’24: $280MQ4 ’24Q1 ’25: $395MQ2 ’25: $416MQ2 ’25Q3 ’25: $631MQ4 ’25: $706MQ4 ’25Q1 ’26: $499Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 70.1%ADR: 21.6%Other: 4.4%ETP: 3.9%
  • Common Stock · 70.1% · $442M
  • ADR · 21.6% · $136M
  • Other · 4.4% · $28M
  • ETP · 3.9% · $25M

Quarter-over-Quarter Changes full breakdown →

vs Q2 2025 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
QUREUNIQURE NVNEW+658.8K658.8K+$38M$38M
ABVXABIVAX SANEW+225.5K225.5K+$19M$19M
DNTHDIANTHUS THERAPEUTICS INCNEW+108.7K108.7K+$4M$4M
IONSIONIS PHARMACEUTICALS INCNEW+60.2K60.2K+$4M$4M
NKTRNEKTAR THERAPEUTICSNEW+58.0K58.0K+$3M$3M
CENTESSA PHARMACEUTICALS PLCNEW+133.3K133.3K+$3M$3M
RAPPRAPPORT THERAPEUTICS INCNEW+64.6K64.6K+$2M$2M
OCULOCULAR THERAPEUTIX INCNEW+141.1K141.1K+$2M$2M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2025

48 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1INSMINSMED INChistory →COM PAR $.0116.71%$105M732.2K
2ARGXARGENX SEhistory →SPONSORED ADR9.16%$58M78.3K
3SOLENO THERAPEUTICS INCCOM7.20%$45M672.2K
4VRNAVERONA PHARMA PLChistory →SPONSORED ADS6.41%$40M379.0K
5QUREUNIQURE NVhistory →SHS6.10%$38M658.8K
6MERUS N VCOM4.43%$28M296.8K
7UGLPROSHARES TR IIhistory →ULTRA GOLD3.92%$25M537.4K
8LLYELI LILLY & COhistory →COM3.47%$22M28.7K
9VRTXVERTEX PHARMACEUTICALS INChistory →COM3.42%$22M55.1K
10ABVXABIVAX SAhistory →SPONSORED ADS3.03%$19M225.5K
11TRVITREVI THERAPEUTICS INChistory →COM2.90%$18M2.00M
12BSXBOSTON SCIENTIFIC CORPhistory →COM2.84%$18M183.2K
13ALNYALNYLAM PHARMACEUTICALS INChistory →COM2.50%$16M34.6K
14DGXQUEST DIAGNOSTICS INChistory →COM2.47%$16M81.7K
15AZNNASTRAZENECA PLChistory →SPONSORED ADR2.32%$15M190.8K
16EYPTEYEPOINT PHARMACEUTICALS INChistory →COM NEW1.42%$9M628.4K
17REGNREGENERON PHARMACEUTICALSCOM0.95%$6M10.7K
18NAMSNEWAMSTERDAM PHARMA COMPANYORDINARY SHARES0.88%$6M194.8K
19RVMDREVOLUTION MEDICINES INCCOM0.77%$5M104.2K
20AVIDITY BIOSCIENCES INCCOM0.76%$5M110.1K
21DNTHDIANTHUS THERAPEUTICS INCCOM0.68%$4M108.7K
22IONSIONIS PHARMACEUTICALS INCCOM0.62%$4M60.2K
23VKTXVIKING THERAPEUTICS INCCOM0.61%$4M146.2K
24SRRKSCHOLAR ROCK HLDG CORPCOM0.57%$4M96.3K
25ABBVABBVIE INCCOM0.53%$3M14.5K
26NKTRNEKTAR THERAPEUTICSCOM NEW0.52%$3M58.0K
27CENTESSA PHARMACEUTICALS PLCSPONSORED ADS0.51%$3M133.3K
28ASNDASCENDIS PHARMA A/SSPONSORED ADR0.39%$2M12.2K
29MLYSMINERALYS THERAPEUTICS INCCOM0.34%$2M56.6K
30UTHRUNITED THERAPEUTICS CORP DELCOM0.33%$2M5.0K
31TGTXTG THERAPEUTICS INCCOM0.31%$2M54.5K
32RAREULTRAGENYX PHARMACEUTICAL INCOM0.31%$2M64.5K
33RAPPRAPPORT THERAPEUTICS INCCOM0.30%$2M64.6K
34OCULOCULAR THERAPEUTIX INCCOM0.26%$2M141.1K
35XENEXENON PHARMACEUTICALS INCCOM0.25%$2M40.0K
36IRENIREN LIMITEDORDINARY SHARES0.25%$2M33.2K
37PTGXPROTAGONIST THERAPEUTICS INCCOM0.24%$2M23.0K
38BTSGBRIGHTSPRING HEALTH SVCS INCCOM0.19%$1M41.6K
39BHVNBIOHAVEN LTDCOM0.19%$1M80.0K
40KNSAKINIKSA PHARMACEUTICALS INTLORD SHS CL A0.18%$1M29.2K
41BBIOBRIDGEBIO PHARMA INCCOM0.17%$1M20.4K
42MREOMEREO BIOPHARMA GROUP PLCSPON ADS0.16%$979,244475.4K
43SRPTSAREPTA THERAPEUTICS INCCOM0.14%$865,22344.9K
44TVTXTRAVERE THERAPEUTICS INCCOM0.12%$738,51030.9K
45MRNAMODERNA INCCOM0.10%$614,75423.8K
46KALVISTA PHARMACEUTICALS INCCOM0.08%$506,14041.6K
47ATYRATYR PHARMA INCCOM NEW0.04%$268,560372.3K
48ALECALECTOR INCCOM0.03%$210,24671.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$499M50May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$706M55Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$631M51Nov 14, 2025RESTATEMENTchanges · EDGAR ↗
Q2 2025$416M37Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$395M38May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$280M37Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$367M45Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$517M46Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$498M49May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$344M31Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$241M27Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$290M34Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$271M36May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$262M25Feb 14, 202313F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.